<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616483</url>
  </required_header>
  <id_info>
    <org_study_id>IUSCC-0661</org_study_id>
    <nct_id>NCT03616483</nct_id>
  </id_info>
  <brief_title>Collection of Specimens and Clinical Data to Create A Bio-repository for Multiple Myeloma</brief_title>
  <official_title>Collection of Specimens and Clinical Data to Create A Bio-repository for the Multiple Myeloma Program: The Indiana Multiple Myeloma Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-interventional, observational study. The purpose of this study is
      to collect data and bio-specimens that will support future research
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Create a repository</measure>
    <time_frame>5 years</time_frame>
    <description>The primary objective of this study is to provide a mechanism to store comprehensive clinical, genomic, demographic, social, environmental and quality of life data from subjects with plasma cell dyscrasias</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Data collection</measure>
    <time_frame>5 years</time_frame>
    <description>To collect data related to clonal evolution, tumor microenvironment, clinical outcomes, adverse events, environmental factors and quality of life that will provide the foundation to create hypotheses for future confirmatory studies.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Plasma Cell Dyscrasias</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is a non-interventional trial</intervention_name>
    <description>This is a non-interventional trial</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      saliva, blood, bone marrow aspirate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients disgnosed with one of the following:

          1. Monoclonal Gammopathy of Undetermined Significance (MGUS)

          2. Smoldering Multiple Myeloma

          3. Multiple Myeloma

          4. Bony or Soft Tissue Plasmacytoma

          5. Primary Amyloidosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients â‰¥ 18 years of age at the time of informed consent

          2. Has been diagnosed with or is suspected to have one of the following:

               1. Monoclonal Gammopathy of Undetermined Significance (MGUS)

               2. Smoldering Multiple Myeloma

               3. Multiple Myeloma

               4. Bony or Soft Tissue Plasmacytoma

               5. Primary Amyloidosis

        Exclusion Criteria:

        &lt; 18 years of age

        Have not been diagnosed with one of the following:

        Monoclonal Gammopathy of Undetermined Significance (MGUS) b.Smoldering Multiple Myeloma
        c.Multiple Myeloma d.Bony or Soft Tissue Plasmacytoma e.Primary Amyloidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Abu Zaid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad Abu Zaid, MD</last_name>
    <phone>317-278-0626</phone>
    <email>MABUZAID@IU.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Abu Zaid, MD</last_name>
      <phone>317-948-7038</phone>
      <email>mabuzaid@iu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Mohammad Abu Zaid, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Monoclonal gammopathy of undetermined significance</keyword>
  <keyword>Plasmacytoma</keyword>
  <keyword>Smoldering multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

